About this trial
This trial is studying ways to screen for targeted treatments in patients with previously treated non-small cell lung cancer. It will help find out which treatments work best based on specific cancer traits. The goal is to improve outcomes by comparing new therapies to standard care. It also includes options for patients who do not fit into the specific treatment groups.
The trial's ID number is NCT03851445. It is a Phase 2 and 3 trial, which means it is looking at how well the treatments work and how safe they are. The trial is regulated by the FDA and aims to include around 10,000 participants.
Who can join
Adults aged 18 and older, both men and women, with a confirmed diagnosis of non-small cell lung cancer can join. Participants should have Stage IV or recurrent disease and meet specific treatment history requirements. The trial team will confirm eligibility based on these criteria.
Condition
Previously Treated Non-Small Cell Lung Cancer
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will go through a screening process to see if they can join one of the treatment sub-studies. This study itself does not involve any treatment but helps assign patients to the right sub-study based on their cancer's characteristics. Each sub-study will then provide its own treatment options.
Where
This trial is running at 1,229 locations in the United States. 950 of them are currently recruiting.
Abbott-Northwestern Hospital
Minneapolis, Minnesota
Adams Cancer Center
Gettysburg, Pennsylvania
Addison Gilbert Hospital
Gloucester, Massachusetts
Adena Regional Medical Center
Chillicothe, Ohio
AdventHealth Hendersonville
Hendersonville, North Carolina
AdventHealth Infusion Center Asheville
Asheville, North Carolina
AdventHealth Infusion Center Haywood
Clyde, North Carolina
AdventHealth Infusion Center Weaverville
Weaverville, North Carolina
The first 8 of 1,229 sites are listed here. The registry record has the full list.